Opioids for agitation in dementia

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 5, 2015, Pages

  Brown, Richard ^a   Howard, Robert ^b   Candy, Bridget ^c   Sampson, Elizabeth L ^c  

^a KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; BUPRENORPHINE; BUTORPHANOL; CODEINE; DEXTROMORAMIDE; DEXTROPROPOXYPHENE; DEZOCINE; DIAMORPHINE; DIHYDROCODEINE; DIPHENOXYLATE; DIPIPANONE; FENTANYL; HYDROCODONE; HYDROMORPHONE; KETOBEMIDONE; LEVORPHANOL; MEPTAZINOL; METHADONE; MORPHINE; NALBUPHINE; OPIATE; OXYCODONE; OXYMORPHONE; PENTAZOCINE; PETHIDINE; PHENAZOCINE; PLACEBO; REMIFENTANIL; SUFENTANIL; NARCOTIC ANALGESIC AGENT;

AGITATION; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; PSYCHOLOGY; PSYCHOMOTOR AGITATION;

ANALGESICS, OPIOID; DEMENTIA; HUMANS; PSYCHOMOTOR AGITATION;

EID: 84945366222     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009705.pub2     Document Type: Review

References (53)

1. Buffum MD, Sands L, Miaskowski C, Brod M, Washburn A. A clinical trial of the effectiveness of regularly scheduled versus as-needed administration of acetaminophen in the management of discomfort in older adults with dementia. Journal of the American Geriatrics Society 2004; Vol. 52, issue 7:1093-7.
2. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 2011;343:d4065. [DOI: 10.1136/bmj.d4065; PUBMED: 21765198]
3. Kurrle S, Cameron I. The role of morphine in late stage dementia. Practical Solutions in Dementia Care. Handbook and Abstracts of the 5th National Conference, Alzheimer's Association Australia. Alzheimer's Association Australia, 1995.
4. Manfredi PL, Breuer B, Wallenstein S, Stegmann M, Borromly G, Libow L. Opioid treatment for agitation in patients with advanced dementia. International Journal of Geriatric Psychiatry 2003;18:700-5. [DOI: 10.1002/gps.906]
5. Passmore MJ. Sublingual sufentanil for incident pain and dementia-related response agitation. International Psychogeriatrics 2011;23(5):844-6. [DOI: 10.1017/S1041610211000275; PUBMED: 21349237]
6. Sloan JP. Morphine for behavior control in dementia. Journal of the American Geriatrics Society 1989;37(1):89. [PUBMED: 2521229]
7. Pain relief as a treatment for agitation and aggression in persons with dementia. Ongoing study Anticipated date of first participant enrolment: 1/03/2011.
8. Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT). Ongoing study October 2007.
9. American Geriatric Society Panel. The management of chronic pain in older persons. Journal of the American Geriatric Society 1998 May;46(5):635--51. [PUBMED: 9588381]
10. American Geriatric Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. Journal of the American Geriatric Society 2009 Aug;57(8):1331-46. [DOI: 10.1111/j.1532-5415.2009.02376.x; PUBMED: 19573219]
11. Alzheimer's Disease International. World Alzheimer Report 2009. London: Alzheimer's Disease International, 2009.
12. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology 2009;8(2):151-7. [PUBMED: 19138567]
13. Banerjee S. The use of antipsychotic medication for people with dementia: time for action. A report for the Minister of State for Care Services. London: Department of Health, 2009.
14. Bernabei R, Gambassi G, Lapane K, Landi F, Gatsoni C, Dunlop R, et al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. JAMA 1998;279(23):1877-82. [PUBMED: 9634258]
15. Bodnar RJ. Endogenous opiates and behavior: 2009. Peptides 2010;31(12):2325-59. [PUBMED: 20875476]
16. Brown R. Broadening the search for safe treatments in dementia agitation - a possible role for low-dose opioids?. International Journal of Geriatric Psychiatry 2010;25(10):1085-6. [PUBMED: 20872931]
17. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimers disease. IV: Disorders of behaviour. British Journal of Psychiatry 1990;157:86-94. [PUBMED: 2397368]
18. Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD003476.pub2; PUBMED: 16437455 ]
19. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM. Long-term opioid management for chronic noncancer pain. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD006605.pub2; PUBMED: 20091598]
20. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008191.pub2]
21. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly: I. A conceptual review. Journal of the American Geriatrics Society 1986;34(10):711-21. [PUBMED: 3531296]
22. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. Journal of Gerontology 1989;44(3):M77-84. [PUBMED: 2715584]
23. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44(12):2308-14. [PUBMED: 7991117]
24. Fainsinger R, Waller A, Bercovici M, Bengtson K, Landman W, Hosking M, et al. A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliative Medicine 2000;14(4):257-65. [PUBMED: 10974977]
25. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. International Psychogeriatrics 1996;8 Suppl 3:497-500. [PUBMED: 9154615]
26. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12(3):189-98. [PUBMED: 1202204]
27. Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, et al. Efficacy of memantine for agitation in Alzheimer's dementia: A randomised double-blind placebo controlled trial. PLoS ONE 2012;7(5):e35185. [DOI: 10.1371/journal.pone.0035185; PUBMED: 22567095]
28. Helmes E, Csapo KG, Short JA. Standardization and validation of the Multidimensional Observation Scale for Elderly Subjects (MOSES). Journal of Gastroenterology 1987;42(4):M395-M495. [PUBMED: 3598087]
29. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org, 2009.
30. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. British Journal of Psychiatry 1982;140:566-72. [PUBMED: 7104545]
31. Husebo BS, Strand LI, Moe-Nilssen R, Husebo SB, Ljunggren AE. Pain in older persons with severe dementia. Psychometric properties of the Mobilization-Observation-Behaviour-Intensity-Dementia (MOBID-2) Pain Scale in a clinical setting. Scandinavian Journal of Caring Sciences 2010;24(2):380-91. [DOI: 10.111/j.1471-6712.2009.00710.x; PUBMED: 20210897]
32. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 2011;343:d4065. [DOI: 10.1136/bmj.d4065]
33. Husebo BS, Ballard C, Aarsland D. Pain treatment of agitation in patients with dementia: a systematic review. International Journal of Geriatric Psychiatry 2011;26(10):1012-8. [DOI: 10.1002/gps.2649; PUBMED: 21308784]
34. Husebo BS, Ballard C, Cohen-Mansfield J, Seifert R, Aarsland D. The response of agitated behavior to pain management in persons with dementia. American Journal of Geriatric Psychiatry 2014 July;22(7):708-17. [DOI: 10.1016/j.jagp.2012.12.006; PUBMED: 23611363]
35. Leknes S, Tracey I. A common neurobiology for pain and pleasure. Nature Neuroscience 2008;9(4):314-20. [PUBMED: 18354400]
36. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JCS. Mental and behavioural disturbances in dementia: findings from the Cache County Study on Memory in Aging. American Journal of Psychiatry 2000;157(5):708-14. [PUBMED: 10784462]
37. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44. [PUBMED: 2358819]
38. McLachlan AJ, Bath S, Naganathan V, Hilmer SN, Le Couteur DG, Gibson SJ, Blyth FM. Clinical pharmacology of analgesic medicines in older people: impact of frailty and cogntive impairment. British Journal of Clinical Pharmacology 2011;71(3):351-64. [DOI: 10.1111/j.1365-2125.2010.03847.x]
39. Morrison RS, Sui AL. A comparison of pain and its treatment in advanced dementia and cognitively intact patients with a hip fracture. Journal of Pain and Symptom Management 2000;19(4):240-8. [PUBMED: 10799790]
40. O'Neil CK, Hanlon JT, Marcum ZA. Adverse effects of analgesics commonly used by older adults with osteoarthritis: Focus on non-opioid and opioid analgesics. The American Journal of Geriatric Pharmacotherapy 2012;10(6):331-42. [DOI: 10.1016/j.amjopharm.2012.09.004]
41. Papleontiou M, Henderson CR, Turner BJ, Moore AA, Olkhovskaya Y, Amanfo L, Carrington Reid M. Outcomes associated with opioid use in the treatment of chronic non-cancer pain among older adults: A systematic review and meta-analysis. Journal of the American Geriatric Society 2010;58(7):1353-69. [DOI: 10.1111/j.1532-5415.2010.02920.x]
42. Pieper MJC, van Dalen-Kok AH, Franke AL, van der Steen JT, Scherder EJA, Husebo BS, Achterberg WP. Interventions targeting pain or behaviour in dementia: A systematic review. Ageing Research Reviews 2013;12(4):1042-55. [DOI: 10.1016/j.arr.2013.05.002; PUBMED: 23727161]
43. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakais C, Ismail Z, et al. for the CitAD Research Group. Effect of Citalopram on Agitation in ALzheimer's disease: The CitAD Randomised Clinical Trial. JAMA 2014;311(7):682-91. [DOI: 10.1001/jama.2014.93; PUBMED: 24549548]
44. Rabinowitz J, Davidson M, De Deyn PP, Katz I, Brodaty H, Cohen-Mansfield J. Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. American Journal of Geriatric Psychiatry 2005;13(11):991-8. [PUBMED: 16286443]
45. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. American Journal of Psychiatry 1982;139(9):1136-9. [PUBMED: 7114305]
46. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294(15):1934-43. [PUBMED: 16234500]
47. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine 2006;355(15):1525-38. [PUBMED: 17035647]
48. Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technology Assessment 2005;9(10):1-93, iii-iv. [PUBMED: 15774233]
49. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. American Journal of Psychiatry 2008;165(7):844-54. [PUBMED: 18519523]
50. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. American Journal of Psychiatry 1998;155(1):54-61. [PUBMED: 9433339]
51. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 2001;293:311-5. [PUBMED: 11452128]
52. Zubieta JK, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA, Koeppe RA. Regulation of human affective responses by anterior cingulate and limbic-opioid neurotransmission. Archives of General Psychiatry 2003;60(11):1145-53. [PUBMED: 14609890]
53. Zuidema S, Koopmans R, Verhey F. Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. Journal of Geriatric Psychiatry and Neurology 2007;20(1):41-9. [PUBMED: 17341770]